论文部分内容阅读
目的:观察急性中度脑梗死患者血浆IL-13水平在灯盏细辛注射液治疗前后的诊断意义。方法:使用放射免疫方法测定102例急性中度脑梗死患者治疗前后IL-13水平并与对照组30例进行比较分析。结果:第7天,两组血清IL-13水平最高;第7、14天,治疗组血清IL-13水平低于对照组,两组比较,有统计学差异(P<0.05或P<0.01);治疗组神经功能缺损程度明显较对照组减轻,差异均有显著性(P<0.05,P<0.01)。结论:灯盏细辛注射液通过抑制急性脑梗死患者的炎症反应,改善患者的预后。
OBJECTIVE: To investigate the diagnostic value of plasma IL-13 levels in patients with acute moderate cerebral infarction before and after the treatment of Dengzhanxincin injection. Methods: The levels of IL-13 in 102 patients with acute moderate cerebral infarction before and after treatment were measured by radioimmunoassay and compared with 30 patients in control group. Results: On the 7th day, serum IL-13 level was the highest in both groups. On the 7th and 14th days, serum IL-13 level in the treatment group was lower than that in the control group. There was significant difference between the two groups (P <0.05 or P <0.01) The degree of neurological deficit in the treatment group was significantly lower than that in the control group (P <0.05, P <0.01). Conclusion: Erigeron breviscapus injection can improve the prognosis of patients by inhibiting the inflammatory reaction in patients with acute cerebral infarction.